• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Marvai LifeSciences Holdings, Inc. Shareholders with Large Losses are Encouraged to Contact Robbins LLP for Information About Leading the Securities Fraud Class Action Lawsuit Against MRVI

By: Robbins LLP via GlobeNewswire
March 12, 2025 at 17:49 PM EDT

SAN DIEGO, March 12, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) securities between August 7, 2024 and February 24, 2025. Maravai is a life sciences company that provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

The Allegations: Robbins LLP is Investigating Allegations that Maravai LifeSciences Holdings, Inc. (MRVI) Intentionally Recorded Unearned Revenues

According to the complaint, during the class period, defendants failed to disclose to investors that: (1) Maravai lacked adequate internal controls over financial reporting related to revenue recognition; (2) as a result, the Company inaccurately recognized revenue on certain transactions during fiscal 2024; (3) its goodwill was overstated; and (4) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On February 25, 2025, Maravai revealed it identified an error in revenue recognition and "a material weakness in its internal controls over revenue recognition. On this news, the price of the Company's stock fell over 21% to close at $3.14 per share on February 25, 2025.

What Now: You may be eligible to participate in the class action against Maravai LifeSciences Holdings, Inc. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by May 5, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against Maravai LifeSciences Holdings, Inc. or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contact:
Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

https://www.facebook.com/RobbinsLLP/
https://www.linkedin.com/company/robbins-llp/

A photo accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/76014780-8516-4b60-92f3-fca3f8e8146f


Primary Logo

More News

View More
3 Potential Scenarios to Watch for in D-Wave's Earnings Report
Today 18:19 EST
Via MarketBeat
Tickers QBTS
Eli Lilly Posts Stellar Q3: Long-Term Upside Is Well in Play
Today 17:20 EST
Via MarketBeat
Tickers LLY
Uber Is Crushing Lyft—And It’s Not Even Close
Today 16:18 EST
Via MarketBeat
Tickers ADDDF BIDU DASH LCID LYFT MCD
Is Alphabet a Buy After Its Blowout Earnings?
Today 15:24 EST
Via MarketBeat
Tickers GOOGL
Prediction Markets Are Coming: Can DraftKings & FanDuel Survive?
Today 14:04 EST
Via MarketBeat
Tickers DKNG FLUT HOOD

Recent Quotes

View More
Symbol Price Change (%)
AMZN  249.46
-4.54 (-1.79%)
AAPL  270.04
+0.99 (0.37%)
AMD  250.05
-9.60 (-3.70%)
BAC  53.54
-0.02 (-0.04%)
GOOG  278.06
-6.06 (-2.13%)
META  627.32
-10.39 (-1.63%)
MSFT  514.33
-2.70 (-0.52%)
NVDA  198.69
-8.19 (-3.96%)
ORCL  248.17
-9.68 (-3.75%)
TSLA  444.26
-24.11 (-5.15%)
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap